- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diffuse large B-Cell lymphoma
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 920KB)
Polatuzumab vedotin – November 2022
Polatuzumab Vedotin: Powder for I.V. infusion 30 mg, Powder for I.V. infusion 140 mg; Polivy®
Last updated
17 March 2023